Savara (SVRA) PT Raised to $6 at Oppenheimer

Oppenheimer analyst Andreas Argyrides raised the price target on Savara (NASDAQ: SVRA) to $6.00 (from $5.00) while maintaining a Outperform rating.

The analyst commented: "On 8/13, Savara (SVRA) reported 2Q25 financials and provided a business update. Following a Type A meeting with the FDA, management announced alignment on CMC information required to resubmit the BLA for MOLBREEVI in aPAP, now planned for December 2025, with FUJIFILM as the new drug substance manufacturer. With the sole deficiency around CMC addressed, Savara is on track for a potential August 2026 approval, if granted Priority Review. Given the unmet need for therapies in aPAP and the robust Ph3 IMPALA-2 data, we continue to view MOLBREEVI as well-positioned for commercial success, with ~1,000 patients in line of sight at the time of launch. In addition, the company expects to submit an MAA to the EMA and UK MHRA in 1Q26. We reiterate Outperform, raise PT to $6 (from $5)."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Aurora Spine settles patent dispute, secures $600K insider loan
• Mosaic sets pricing for tender offers on up to $1.4B in debt